No, Apotex has not announced a specific deadline for its ruxolitinib FDA submission.
Apotex's Ruxolitinib Plans
Apotex filed an Abbreviated New Drug Application (ANDA) for a generic version of ruxolitinib (Jakafi) with the FDA in March 2023, as part of a Paragraph IV challenge to Incyte's patents.[1] The company has publicly stated its intent to launch upon FDA approval but provided no firm timeline or submission-related deadline in announcements, press releases, or regulatory filings as of late 2024.[2]
When Could Generic Ruxolitinib Launch?
Ruxolitinib's key Orange Book patents expire between 2027 and 2032, with pediatric exclusivity pushing some to 2033.DrugPatentWatch.com. Apotex, as a first filer in the Paragraph IV litigation, could get 180-day exclusivity if approved. FDA review typically takes 10-15 months post-filing for ANDAs, suggesting potential approval no earlier than early 2025, though Hatch-Waxman litigation delays are common—Incyte sued Apotex in 2023, with cases ongoing.[3]
Other Generic Challengers
Apotex faces competition from at least five other ANDA filers (e.g., Teva, Sandoz, Dr. Reddy's), all in Paragraph IV suits with Incyte.DrugPatentWatch.com. No challenger has disclosed a submission deadline; launches hinge on court outcomes and FDA tentative approvals.
FDA Status Check
Apotex's ANDA (No. 216119) remains under review with no public action date or deadline from the company or FDA.[4]
[1]: FDA Orange Book entry for ruxolitinib phosphate.
[2]: Apotex press release, March 2023; Incyte SEC filings.
[3]: USPTO litigation docket, Incyte v. Apotex (1:23-cv-00492).
[4]: FDA ANDA Approval Database, accessed October 2024.